Tactile Systems Technology, Inc. (TCMD) fair value analysis
Nasdaq · Updated 2026-10-19
TCMD price how computed
Forward Fair Value verdict
UndervaluedTCMD is trading at a 10–25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $22.52
- Sector
- Healthcare
- 12-month range
- $15.00–$33.05
- Market cap
- $510M
- From 52-week high
- -31.9%
- Shares outstanding
- 22.7M
- Rank in Healthcare by discount to fair value
- #39 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Tactile Systems Technology, Inc. is a medical device company that develops and markets pneumatic compression devices used to treat lymphedema, venous insufficiency, and other circulatory conditions. The company operates primarily in the United States and serves patients through healthcare providers and clinics.
TCMD currently ranks #39 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 11 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $510M
- P/E (trailing)
- 19x
- Revenue (TTM)
- $350M
- Net margin
- 7.1%
- EPS (TTM)
- $1.16
- Gross margin
- 68.7%
- Debt / equity
- 0.06
- Revenue growth (3-yr avg)
- 7.7%
- Shares outstanding
- 22.7M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Stable
- 52-week position
- The lower-middle quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 50 · neutral
- 50-day average
- $23.05
- 200-day average
- $26.19
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-02
- Last 8 quarters vs consensus
- 6 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+142.9%)
2026-03 ▲ beat (+106.0%)
2025-12 ▲ beat (+3.4%)
2025-09 ▲ beat (+71.4%)
2025-06 ▬ met (0.0%)
2025-03 ▼ miss (-83.3%)
2024-12 ▲ beat (+41.8%)
2024-09 ▲ beat (+47.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 4 buy · 0 hold · 0 sell (4 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $37.7
- Target vs last price
- +67.4%
What our data shows for TCMD
- Our model validated 13 trailing price-to-earnings windows for TCMD, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $15.00–$33.05.
- The 14-day relative strength index sits at a neutral 50.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for TCMD
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent TCMD news
TickrTrends' derived news-sentiment signal for TCMD is currently leaning positive, computed from recent coverage.
- TCMD Maintained by BTIG -- Price Target Lowered to $35.00 (gurufocus.com, 2026-10-12)
TickrTrends take: BTIG's decision to lower its price target while maintaining coverage suggests analyst conviction in TCMD's business fundamentals despite near-term headwinds, which aligns with TickrTrends' undervalued assessment for this Healthcare sector company. The gap between BTIG's $35 target and the current market price represents the key metric for investors monitoring whether the market recognizes the valuation opportunity that TickrTrends has identified. Readers should track whether other analysts follow with similar target adjustments and whether TCMD's operational performance validates or challenges the undervalued positioning over coming quarters.
What people are saying
Follow the TCMD conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — TickrTrends' derived indicators for TCMD showed improvement this week, with the stock's sector discount rank rising from number 56 to number 51. The company maintains an undervalued valuation verdict within the Healthcare sector.
- 2026-09-28 — TickrTrends' derived indicators for TCMD showed shifting signals this week within the Healthcare sector. The DCF cross-check band moved from fairly valued to overvalued, while the 50/200-day trend state transitioned from mixed to downtrend, indicating weakening momentum. Despite these deteriorating technical and valuation signals, the current overall valuation verdict remains undervalued.
- 2026-09-21 — TickrTrends' derived indicators for TCMD reflect a shift in the company's valuation assessment this week. The DCF cross-check band moved from overvalued to fairly valued, representing a meaningful adjustment in the valuation model. TCMD currently carries an undervalued designation according to TickrTrends' overall valuation verdict.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is TCMD stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), TCMD is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is TCMD's TickrTrends verdict?
TCMD's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does TCMD compare to other Healthcare stocks?
TCMD ranks #39 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is TCMD overbought or oversold?
TCMD's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does TCMD report earnings next?
TCMD's next earnings report is scheduled for 2026-11-02, per the published earnings calendar.
Does TCMD usually beat earnings estimates?
Over its last 8 reported quarters TCMD beat the consensus estimate 6 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about TCMD?
Of 4 analysts covering TCMD, 4 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $37.7 (+67.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
TCMD vs BAX · TCMD vs BDX · TCMD vs BTSG · TCMD vs ENSG · TCMD vs INVA